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Purpose: The purpose of this study was to assess the contribution of ongoing graft 
surveillance tomaximize long-term patency of lower limb in situ saphenous vein bypasses. 
Methods: From January 1981 to October 1994, 556 autogenous grafts were constructed 
in 499 patients. The distal anastomosis was at the popliteal level in 207 (37%) and the tibial 
level in 349 (63%). All patients were enrolled in a prospective surveillance protocol to 
identify lesions that compromise graft patency and were evaluated at 1 day, 1 week, 6 
weeks, and 3 months. Surveillance studies were then obtained every 3 months for the first 
2 postoperative y ars and every 6 months thereafter. 
Results: Four-hundred-fifty abnormalities were detected in236 grafts. The median interval 
from the initial procedure to detection of an abnormality was 12 months (range 0 to 113 
months) and varied with the location of the defect. Later in the life of the graft, progression 
of atherosclerotic disease manifested asinflow obstruction at a median of 15 months, and 
outflow disease threatened the graft at a median of 29 months (r = 0.0003). Of the 450 
surveillance abnormalities, 294 (65%) occurred within the first 2 years after operation, and 
156 (35%) developed more than 2 years after operation. Of the 236 grafts that developed 
surveillance abnormalities, 50 (21%) developed the initial defect more than 2 years after 
the initial bypass procedure. Eleven percent of grafts remaining free of abnormality after 
2 years went on to fail. Sixty-seven i terventions were performed on 62 extremities after 
24 months, with 30 involving previously unrevised grafts. 
Conclusions: Because lesions amenable to revision continue to develop years after vein 
bypass construction, perpetual surveillance is required to ensure optimal rates of graft 
patency. (J VAsc SURG 1996;23:18-27.) 
The emphasis for improving graft patency of 
infrainguinal autogenous vein bypass grafts has 
evolved over the last two decades. Initially, attempts 
were made to improve operative results by develop- 
ing better surgical techniques and improving patient 
selection with improved angiographic imaging. 
More recently, the emphasis was broadened to 
attempt to prevent patent grafts from failing in the 
follow-up period by detecting raft-threatening le- 
sions with prospective ongoing graft surveillance 
protocols) 9 Up to one third of grafts will require 
intervention to prevent failure in the follow-up 
From the Department of Vascular Surgery, Medical College of 
Wisconsin, and the Vascular Surgery Service, Zablocki V. A. 
Medical Center, Milwaukee. 
Presented at the Forty-third Scientific Meeting of the International 
Society for Cardiovascular Surgery, North American Chapter, 
New Orleans, La., June 13-14, 1995. 
Reprint requests: Jonathan B. Towne, MD, Department of
Vascular Surgery, Box 145, 8700 W. Wisconsin Ave. Milwau- 
kee, WI 53226. 
24/6/69164 
18 
period because of the development of lesions that 
threaten patency in the conduit, anastomotic sites, 
and inflow and outflow vessels) ~The particular type 
of lesion varies with the time course in the follow-up 
period. Problems related to technical aspects of the 
procedure occur in the perioperative period (less than 
30 days), complications of fibrointimal hyperplasia 
(vein valve stenosis, graft stricture) occur during the 
1- to 24-month period, and progression of athero- 
sclerotic disease in inflow, outflow, and the vein 
conduit itself occur beyond 24 months.l~ Because the 
autogenous vein is living tissue, secondary patency 
rates are better if lesions that lead to graft failure can 
be detected before thrombosis, preventing transmu- 
ral injury to the vein, which in turn reduces the 
chances of salvaging the conduit. 12 
Recent studies have identified grafts that are more 
prone to develop problems in the follow-up period. 
We have demonstrated that grafts constructed with 
spliced vein segments and those veins requiring repair 
of an injury during the initial procedure are at higher 
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risk for failure.I~ Similar results were noted by Taylor 
et al. 13 in a series of reversed vein grafts. More 
recently, Mills et al. 12 noted an increased incidence of 
conduit-threatening lesions in grafts that had abnor- 
malities detected early in the postoperative period 
during routine graft surveillance. 
Studies to date have documented the ability to 
detect lesions that may adversely affect graft 
patency. H~ Because of the lack of long-term 
fbllow-up, the need for continued graft surveillance 
ha~ not been documented. This study attempts to 
quantitate the value of ongoing long-term graft 
surveillance in a series of patients with autogenous 
vein grafts who have been enrolled in a prospective 
surveillance protocol. 
METHODS 
From January 1981 to October 1994, 556 
consecutive lower extremity autogenous vein by- 
passes were performed on 380 men and 119 women 
at the affiliated hospitals of the Medical College of 
Wisconsin. Patient records from the vascular labora- 
tories at the Medical College of Wisconsin and the 
Clement J. Zablocki Veterans Affairs Medical Center, 
Milwaukee, Wis., were reviewed to evaluate the 
efficacy of a long-term vein graft surveillance pro- 
gram. The vascular laboratory record contains" sum- 
maries of the operation, diagnostic angiograms, and 
intraoperative assessment, aswell as the records of all 
graft velocities. 
In situ saphenous vein was the conduit used in 
539 (97%) of the cases. The remaining 17 (3%) 
conduits consisted of in situ saphenous vein compos- 
ite with autogenous vein. Fifty-seven (11%) of the 
patients had bilateral in situ saphenous vein bypasses. 
The indication for the procedure was known in 461 
patients and was critical limb ischemia, defined as the 
presence of rest pain, nonhealing ulceration, or 
gangrene, m 93% (n = 427), popliteal artery aneu- 
rysm in 4% (n = 19), and claudication in 3% 
(n = 15). The operative technique for the in situ 
saphenous vein bypass has been previously reported 
and has remained constant for the entire series. ~,m 
Preoperative aortofemoral arteriography was per- 
formed in all cases to identify the site for proximal 
and distal anastomosis. Intraoperative identification 
of residual defects in the conduits (residual valve 
leaflets, persistent arteriovenous fi tulas) or technical 
errors that caused hemodynamic abnormalities was 
performed with pulsed-wave Doppler spectral anal- 
ysis or color-flow duplex ultrasonography. Comple- 
tion arteriography was performed to ensure technical 
adequacy of the repair. 
The patients were monitored by a prospective 
surveillance protocol consisting of clinical evaluation 
and serial noninvasive hemodynamic testing. Initial 
postoperative studies were pertbrmed at 1 day, 1 
week, 6 weeks, and 3 months. The studies on 
postoperative day 1 were obtained at a standard 
above-knee site for femoropopliteal grafts and above- 
knee and below-knee sites for femorotibial grafts. 
The site chosen is a segment of the vein with uniform 
diameter. This site is determined by review of the 
intraoperative angiogram and is usually 6 inches 
above the knee, 6 inches below the knee, or both. 
These results are compared with intraoperative data 
to assess continued adequate hemodynamic function 
of the conduit. 1~ For the first 2 years patients were 
evaluated eve U 3 months. Beyond 2 years patients 
were evaluated every 6 months. The surveillance 
protocol included the measurement of resting limb 
and toe arterial pressure by the transcutaneous 
Doppler ultrasonographic flow detection technique. 
Graft flow velocity and blood flow patterns were 
evaluated at multiple areas of the graft by use of 
transcutaneous Doppler spectral analysis to identify 
low flow states. Duplex ultrasonography identified 
specific structural abnormalities in the graft, its 
anastomoses, and the inflow and outflow vessels. 
With the introduction of color-flow imaging, duplex 
ultrasonography offers the additional advantage of 
permitting rapid mapping of large sections of graft 
tbr abnormal flow patterns and areas of increased 
peak systolic flow velocity suggestive of stenosis. 
The surveillance technique was not changed at 
any time in the follow-up period. If revision was 
performed or if a surveillance abnormality was 
detected, the surveillance interval was decreased to 
every 3 months. If findings were suspicious but 
inconclusive, they were repeated in 1 month. 
Routine surveillance is done by the vascular 
technologist who performs aphysical examination of 
the leg and obtains hemodynamic data. Any signifi- 
cant change is reported to the attending surgeon. 
Depending on the severity of change, the response 
varies from shortening the surveillance interval to 1 
to 3 months to immediate hospitalization with 
angiography. This latter course of action is generally 
limited to grafts with staccato-type signals, which is 
a marker of imminent occlusion. 
For the purpose of this study, abnormal findings 
detected uring postoperative surveillance were de- 
fined as the presence of postoperative arteriovenous 
fistulas, retained valves, structural abnormalities such 
as graft aneurysm and anastomotic pseudoaneurysm, 
a decrease in ankle/brachial index of 0.15, low flow 
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velocity less than 45 cm/sec, and focal high flow 
velocity greater than 125 cm/sec suggesting 50% to 
75% graft diameter eduction. 9"~~ Low graft flow 
velocity is defined as a change in graft flow measure- 
ments noted on serial evaluations that cannot bc 
explained on the basis of increasing vein graft 
diameter. Hemodynamic abnormalities monitored 
over time were listed in the time interval that the 
abnormality was initially detected. Detection of low 
flow velocity or a graft stenosis with greater than 50% 
diameter reduction prompted angiography and sub- 
sequent revision of the bypass. Inflow or outflow 
arterial lesions were corrected if they adversely 
affected graft hemodynamics. For example, if an 
inflow or outflow lesion resulted in significant 
decrease in an ankle/brachial index (>0.15) or 
significant decrease in graft flow velocity measure- 
ment ( > 20 cm/sec), arteriography and graft revision 
would be recommended. The presence of a stable 
graft flow velocity less than 45 cm/sec as might occur 
in large-diameter conduits was not considered a 
surveillance abnormality. The frequency of abnor- 
malities detected by surveillance, the location (inflow 
vessel, proximal anastomosis, graft, distal anastomo- 
sis, outflow vessel), and any subsequent intervention 
were included in the study for analysis. 
Primary patency was defined according to Society 
for Vascular Surgery/International Society for Car- 
diovascular Surgery-suggested standards for reports 
dealing with lower extremity ischemia. ~'~ Grat~s 
requiring revisions or minor procedures before 
occlusion to prevent graft failure such as ligation of 
arteriovenous fistula or incision of competent valve 
cusp were excluded from primary patency status. 
However, inflow or outflow procedures performed 
remote from the bypass and its two anastomoses did 
not disqualify the graft from primary patency as per 
the "Ad Hoc Committee on Reporting Standards." 
For example, balloon dilation of a common iliac 
artery stenosis would not interrupt primary patency 
for a femoropopliteal graft. The cause and location of 
the abnormality leading to revision was recorded, as 
well as the presence of graft thrombosis before 
revision. 
The data were analyzed by use of SPSS for 
Windows (Version 6.0.1; SPSS Inc., Chicago, Ill.). 
Comparisons between individual-dependent and 
-independent categorical variables were performed 
by use of Pearson's chi-square analysis or Fisher's 
exact est for minimum expected frequencies less than 
5 (p <_ 0.05 considered significant). Nonparametric 
comparisons were made by use of Kruskal-Wallis 
one-way analysis of variance (ANOVA) and the 
Wilcoxon rank sum test. The cumulative patient 
survival and primary and secondary graft patency 
rates were examined by use of life-table analysis. The 
effect of independent factors on graft patency was 
evaluated by use of Kaplan-Meier analysis and the 
log-rank statistic. 
RESULTS 
The median patient follow-up was 35 months 
(range 0 to 137 months). The distal anastomosis was 
to the popliteal level in 207 (37%) and to the tibial 
vessels in 349 (63%). The cumulative patient survival 
rate for this series was 91% after 1 year, 86% after 2 
years, 68% after 5 years, and 37% after 10 years (Fig. 
1, Table I). The primary and secondary cumulative 
graft patency rates tbr the 556 grafts are illustrated in 
Fig. 2 and Table II. 
Serial hemodynamic data were available for anal- 
ysis in 462 grafts and revealed 450 abnormalities in
236 grafts or limbs. Thus 51% of these grafts 
developed at least one significant abnormality. Of the 
450 surveillance abnormalities, 294 (65%) occurred 
within the first 2 years of the primary bypass and 156 
(35%) occurred more than 2 years after the initial 
surgery. Of the 236 grafts that developed surveillance 
abnormalities, 50 (21%) developed the first abnor- 
mality more than 2 years after the primary bypass. 
The abnormalities are recorded in Table III. For 75% 
of the surveillance abnormalities, the source was 
identified and involved the conduit in 207 (61%), the 
inflow vessel in 44 (13%), the outflow vessel in 39 
(11%), the distal anastomosis n 29 (9%), and the 
proximal anastomosis in 19 (6%). Of the 450 
abnormalities detected in 236 conduits, 170 (38%) 
required intervention. 
The median interval from the initial procedure to 
detection of abnormality was 12 months (range 0 to 
113 months) and varied with the location of the 
defect. Lesions occurred at a median of 6 months in 
the vein conduit, 8.5 months at the proximal 
anastomosis, and 7 months at the distal anastomosis. 
Later in the life of the graft, progression of athero- 
sclerotic disease manifested as inflow obstruction at a 
median of 15 months, and outflow disease threatened 
the graft at a median 29 months (r = 0.0003, 
Kruskal-Wallis one-way ANOVA). The cumulative 
proportion of grafts remaining tree of surveillance 
abnormalities i  illustrated in Fig. 3. Thirty percent 
(50 of 169) of grafts free of abnormalities at 24 
months ubsequently went on to develop at least one 
abnormality during the remaining life of the graft 
(Fig. 4). 
At least one intervention was performed on 169 
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Fig.  1. Cumulative patient survival rate after 556 saphenous vein in situ lower extremity bypass 
grafts between 1981 and 1994. 
Table I. Life-table of cumulative patient survival rate after 556 saphenous vein in situ bypasses 
from 1981 to 1994 
No. patients No. patients No. terminal Interval survival Cumulative survival Standard 
Interval (mo) at risk withdrawn events rate rate error (%) 
0-1 556 34 8 0.99 0.99 0.51 
1-6 514 40 16 0.97 0.95 0.91 
6-12 458 38 18 0.96 0.91 1.25 
12-18 402 25 10 0.97 0.89 1.47 
18-24 367 22 13 0.96 0.86 1.69 
24-30 332 19 7 0.98 0.84 1.85 
30-36 306 26 16 0.95 0.79 2.06 
36-42 264 33 11 0.96 0.76 2.29 
42-48 220 25 6 0.97 0.74 2.55 
48-54 189 20 8 0.96 0.70 2.79 
54-60 161 23 5 0.97 0.68 3.03 
60-66 133 22 5 0.96 0.65 3.34 
66-72 106 15 7 0.93 0.61 3.69 
72-78 84 15 4 0.95 0.57 4.09 
78-84 65 10 1 0.98 0.56 4.62 
84-90 54 10 4 0.92 0.52 4.90 
90-96 40 8 3 0.92 0.48 5.44 
96-102 29 6 1 0.96 0.46 6.25 
102-108 22 3 I 0.95 0.43 6.97 
108-114 18 5 1 0.94 0.41 7.38 
114-120 12 3 1 0.90 0.37 8.44 
of 556 (30%) extremities in 162 patients to maintain 
patency of the graft or limb viability after the initial 
saphenous vein in situ bypass. This included 114 
grafts (67.5%) requiring a single revision, 33 grafts 
(19.5%) requiring 2 revisions, 15 (8.9%) requiring 3 
revisions, 4 (2.3%) requiring 4 revisions, and 3 
(1.8%) requiring 5 revisions. Thirty (18%) of these 
initial interventions occurred more than 24 months 
after the initial saphenous vein in situ bypass. This 
included 23 revisions to graft or anastomoses that 
removed these grafts from primary patency and seven 
extremities that required revisions remote from the 
conduit (e.g., dilation of common iliac stenosis that 
did not affect primary patency). Of the 139 primary 
interventions that were performed within 24 months 
of the initial bypass, 125 (90%) involved the conduit 
or its anastomoses, 10(7%) were inflow procedures, 
2 (1.5%) were outflow procedures, and 2 (1.5%) 
were replacement conduits. For the 30 primary 
interventions occurring more than 24 months after 
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Fig. 2. Life-table analysis of primary and secondary patency rates of 556 saphenous vein in situ 
lower extremity bypasses performed between 1981 and 1994. Squares record primary patency 
rate. Diamonds record secondary patency rate. 
Table II. Life-tables of cumulative primary and secondary graft patency rates for 556 saphenous 
vein in situ bypasses from 1981 to 1994 
No. grafts No. grafts No. grafts Interval Cumulative Standard 
Interval (too) at risk withdrawn failed patency patency error (%) 
Primary graft pa- 
tency 
0-1 556 53 57 0.89 0.89 1.24 
1-12 446 86 73 0.82 0.73 9 1.80 
12-24 287 53 21 0.92 0.67 2.27 
24-36 213 43 8 0.96 0.64 2.63 
36-48 162 51 4 0.97 0.62 3.01 
48-60 107 27 1 0.99 0.62 3.69 
60-72 79 26 5 0.92 0.57 4.21 
72-84 48 18 3 0.92 0.53 5.23 
84-96 27 9 1 0,96 0.50 6.83 
96-108 17 8 1 0,92 0.47 8.25 
108-120 8 7 0 1.00 0.47 12.03 
Secondary graft 
patency 
0-1 556 46 9 0.98 0.98 0.54 
1-12 501 100 22 0.95 0.94 1.06 
12-24 379 62 8 0.98 0.91 1.38 
24-36 309 56 6 0.98 0.89 1.65 
36-48 247 76 1 1.00 0.89 1.88 
48-60 170 45 5 0.97 0.86 2.47 
60-72 120 41 0 1.00 0.86 2.94 
72-84 79 28 2 0.97 0.83 3.83 
84-96 49 22 2 0.95 0.79 5.18 
96-108 25 11 1 0.95 0.75 7.51 
108-120 13 7 0 1.00 0.75 10.41 
the initial bypass, 19 (63%) involved the conduit or 
its anastomoses, five (17%) were inflow procedures, 
five (17%) were outflow procedures, and one (3%) 
was a graft replacement. Over the whole series, a total 
of 256 interventions were performed in 169 extremi- 
ties to maintain graft patency or limb viability after 
the initial bypass. Sixty-seven (26%) were performed 
after 24 months, of which 30 involved previously 
unrevised grafts and 37 were secondary revisions. 
The median interval from the initial vein bypass to 
intervention was 6.5 months for graft revision, 16 
months for inflow procedures, 32.5 months for 
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outflow procedures, and 16 months when a new 
conduit was required (r = 0.0001, Kruskal-Wallis 
one-way ANOVA). 
Primary patency was lost in 174 of 556 grafts 
(31%), including those grafts that were revised after 
occlusion, those that were revised to prevent occlu- 
sion, and those that were not revised after occlusion, 
resulting in a secondary bypass with use of a different 
conduit, amputation, or observation. Early graft 
failure-within 30 days of vein bypass-occurred in 
57 cases (33%), with the remaining 117 (67%) 
primary failures occurring more than 30 days after 
operation. For those grafts remaining primarily 
patent longer than 24 months, the incidence of 
subsequent primary graft failure during the remain- 
ing life of the graft was 11%. This value was 
calculated by dividing the summation of primary 
graft failures occurring after 2 years by the number of 
primarily patent grafts at risk at the beginning of the 
third year of follow-up. Ten percent of grafts 
remaining primarily patent at the beginning of any 
given 1-year interval went on to primary graft failure 
at some point in the life of the graft (Fig. 5). 
DISCUSSION 
Understanding the biology of the autogenous 
vein conduit is essential in attempting to maximize 
patency of these vascular econstructions. The loca- 
tion and natural history of particular lesions that are 
likely to threaten patency of the bypass graft can be 
predicted. In the first 30 days, problems related to the 
operative procedure and patient selection were most 
likely to cause problems. These include technical 
errors in the construction of the anastomosis and, 
when the in situ technique is used, residual compe- 
tent valves and persistent or developing arteriove- 
nous fistulas. In the interval between 1 and 24 
months, the primary cause of graft failure was related 
to fibrointimal hyperplasia. This was identifed as a 
stricture of either the proximal or distal anastomosis 
or more commonly as a stenosis of the conduit at the 
site of valve leaflets or traumatic injury to the vein 
from intraluminal instrumentation required for valve 
disruption. Long strictures related to damage during 
vein harvest or abnormal veins in which fibrotic 
processes, which may have been initiated before the 
bypass by previous episodes of superficial phlebitis, 
can also develop. After 24 months the vein graft was 
most likely to be placed at risk as a result of 
progression of atherosclerotic disease in the inflow 
and outflow vessels, as well as the development of
atherosclerosis in the autogenous vein graft itself. In 
this study, inflow obstruction occurred at a median of 
Table III. Abnormalities detected uring 
surveillance for 462 saphenous vein in situ 
bypasses from 1981 to 1994 
Abnormality No. of gra~s (%) 
Stenosis (high flow velocity) 167 (37%) 
Low flow velocity 100 (22%) 
Decreased ABI or TP 83 (18%) 
Arteriovenous fistula 47 (10%) 
Graft thrombosis 39 (9%) 
Retained valve 7 (1.5%) 
Aneurysm 3 (1%) 
Pseudoaneurysm 3 (1%) 
Distal disease 1 (0.5%) 
Total 450 
ABI, Ankle/brachial index; TP, toe pressure. 
15 months after bypass construction, and outflow 
obstruction developed 29 months into the life of the 
bypass. Lesions in the native arterial system develop 
later than lesions in the conduit, which occurred at a 
median of 8.5 months. 
To achieve optimal secondary patency rates, 
lower extremity vein grafts performed for limb 
salvage require considerable maintenance. Thirty 
percent of the grafts required at least 1 revision. Even 
grafts that have exhibited good hemodynamics forup 
to 24 months are at risk for developing abnormalities 
that could lead to graft failure. In this study 18% of 
initial graft revisions occurred after 24 months. 
Because of the increasing incidence of progression of 
atherosclerosis in inflow and outflow with long-term 
follow-up, a greater percentage of revisions involve 
inflow and outflow vessels as opposed to the conduit 
itself. Of the revisions performed after 24 months, 
68% were to the conduit compared with 85% in the 
earlier time period. 
As the follow-up period becomes longer, degen- 
erativ e changes can develop in the conduit itself. 
Previous work from our institution demonstrated 
that more than 50% of vein bypass conduits followed 
up for at least 5 years demonstrated vidence of 
atherosclerotic degeneration. 11 Often these changes 
represent areas of intimal thickening, but in a 
significant portion the disease had progressed toform 
focal points of stenosis caused by atherosclerosis. As 
noted in this series, patients who require a lower 
extremity bypass for limb salvage have a high 
long-term mortality rate, with 68% of the patients 
alive after 5 years and only 37% surviving 10 years. 
These patient deaths preclude the opportunity to 
monitor this group of vein grafts long enough to 
study the ultimate course of the degenerative pro- 
cesses in the conduit. However, as patient longevity 
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Fig. 3. Cumulative proportion of 462 saphenous vein in situ lower extremity bypass grafts 
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each year of follow-up that subsequently develop at least one significant abnormality during 
postoperative surveillance at sometime during remaining life of graft. 
increases, atherosclerosis formation in the lower 
extremity vein graft is likely to become an increasing 
threat to long-term graft patency. This study dem- 
onstrates that degenerative changes will develop in 
conduits that have been absolutely normal for several 
years of follow-up. The likelihood of developing 
graft-threatening lesions is even greater in conduits 
that have been previously revised or have hemody- 
namic abnormalities, but some conduits that have 
been free of abnormality for 2 years will go on to 
require revision. Recognizing that conduits that 
previously have required revision are more prone to 
develop secondary degenerative processes allows 
surveillance of these conduits to be more focused. 
Other authors have suggested that if he conduit 
has normal hemodynamics in the early perioperative 
period, the chance of problems are such that further 
surveillance may not be warranted. ~2 This study 
reveals that of the 67 graft revisions performed after 
24 months, 37 were to previously revised conduits, 
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but 30 were to vein grafts that had required no 
previous revisions. Conduits that are hemodynami- 
cally normal beyond 2 years evolve lesions at a 
significant rate to warrant ongoing surveillance. The 
average incidence of primary graft failure was 10% of 
the number of grafts remaining primarily patent at 
each yearly time interval beyond 24 months. If 
vascular surgeons want to optimize long-term graft 
patency, surveillance must be done for the life of the 
conduit. 
The importance of detecting raft-threatening 
lesions before thrombosis was again demonstrated in 
this long-term follow-up study. The secondary pa- 
tency rate was 62% at 36 months for grafts that had 
thrombosed compared with 89% for grafts revised 
before thrombosis. In this series, grafts that occluded 
in the first 30 days had a poorer prognosis than those 
that required revision beyond the perioperative 
period (58% vs 79% secondary patency rate at 36 
months) (Table II). Grafts requiring early revision 
identify veins of poor quality that were used as 
conduits, poor patient selection, and technical error. 
Late lesions in contrast primarily reflect degenerative 
changes in the arterial circulation and vein conduit. 
Although this study involved only in situ vein 
bypasses, similar findings have been reported by 
Nehler et al. 2 in a series of reversed autogenous vein 
grafts. It is likely that reversed vein conduits have a 
similar risk for developing surveillance abnormalities 
and primary failure during long-term follow-up as 
our in situ grafts. The difference between the two 
surgical techniques is the higher incidence of revision 
required with the in situ technique during the first 30 
days because of the need to disrupt residual compe- 
tent values and ligate arteriovenous fi tulas. 
A certain amount of practical thinking is needed 
to evaluate patients with grafts at risk. The hemody- 
namic data need to be carefully evaluated and 
correlated with known angiographic status of inflow 
and outflow vessels. It is mandatory that attention 
not be placed on a number such as graft flow less than 
45 cm/sec. A uniform hemodynamic formula cannot 
be applied to every graft, nor can an absolute 
threshold be established todictate the need for graft 
revision. Some grafts followed up long term will 
dilate, resulting in a decreased graft flow velocity. 
Duplex scanning can accurately measure graft diam- 
eters. If the graft flow decreases with rio charge in 
ankie/brachial ndexes and a demonstrable increase is
demonstrated in graft diameter, graft revision is not 
indicated. Ifa trend is noted showing decreasing graft 
flow velocities with or without falling ankle/brachial 
indexes, these patients hould be monitored more 
closely. It is essential for the surgeon to explain any 
hemodynamic changes and to formulate a plan to 
monitor them. 
This study has attempted to identify factors that 
will achieve patency for lower extremity vein bypass 
grafts to determine the best long-term patency that 
could be obtained. For surgeons committed to the 
philosophy of obtaining the best possible long-term 
results, a program of perpetual graft surveillance 
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must be included in the long-term care o f  the 
patients. The fiscal commitment  to maintain a 
comprehensive graft surveillance regimen eeds to be 
identified. It  will be up to social planners to 
determine the ultimate value of  the lower limb. 
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DISCUSSION 
Dr. Joseph L. Mills (Tucson, Ariz.). This study 
represents he results of a 14-year experience with duplex- 
based inftainguinal graft surveillance, which is one of the 
largest series with the longest follow-up reported to date. 
Serial studies were available for analysis in 462 grafts, 97% 
of which were in situ vein conduits. In reviewing the 
authors' detailed manuscript, one is struck by the concor- 
dance of the authors' data with nearly all previous reports. 
Szilagyi's classic report, published 32 years ago, noted the 
development of graft-threatening lesions in one third of 
infrainguinal reverse vein grafts that were monitored by 
arteriography. In this report, 30% of in situ vein grafts 
required at least one revision. 
The types and locations of graft lesions and their 
appearance times are also worth noting. In 1993 we 
reported our 5-year experience with reversed vein graft 
surveillance and noted that 60% of the lesions were 
intrinsic to the vein conduit with a mean repair time of 8 
months after operation; 12.8% were inflow lesions; and 
8.5% were in the outflow tract, which occurred about 20 
months after operation. These figures are virtually identical 
to those in this report for in situ conduits. Also worth 
emphasis is the low incidence of spontaneous graft 
thrombosis in vein grafts that are subjected to meticulous 
surveillance, which was only 8% in our series and 9% in the 
Milwaukee experience. These data strongly suggest hat 
most graft-threatening lesions are intrinsic to the conduit 
and that they can be detected and repaired before graft 
thrombosis by careful surveillance and appropriate inter- 
vention. 
I do differ with the authors' interpretation f their data 
in one respect. In our series 80% of graft lesions that 
required repair were repaired in the first 18 months after 
graft implantation. The Oregon group recently reported 
similar data, and in this report 79% of graft revisions were 
performed within the first 2 years. This clearly indicates that 
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graft surveillance must be intensive in the first 1 to 2 years 
and can be relaxed thereafter if study results are normal. 
And the authors, in fact, have already done this by 
decreasing patient graft surveillance visits to 6- to 12- 
month intervals after the first 2 years. 
The two time intervals with the highest incidence of 
graft revision were 0 to 30 days, during which 9% required 
revision, and 1 to 12 months, during which 15% required 
revision. Do the authors believe that these high rates of 
early graft revision could be reduced by more detailed graft 
evaluation at the time of implantation, either with duplex 
scanning or angioscopic evaluation of the conduit? 
What specific threshold uplex criteria have the authors 
developed? The authors tate that a peak systolic velocity 
greater than 125 cm/sec was considered abnormal, but in 
our practice we rarely operate on lesions with peak systolic 
velocities less than 300 cm/sec or velocity ratios less than 
3.5. 
What is the long-term fate of these intermediate flow 
disturbances? Do the authors have any data on lesion 
progression? 
Forty percent of the abnormalities in this series were 
picked up either by a low flow or diminished ankle/brachial 
indexes. This suggests that some of the late-appearing 
lesions could be picked up with a simpler protocol. If this 
is true, do the authors have any suggestions for late 
fbllow-up? 
Did you identify risk factors for the development of 
graft stenosis? That is, were the stenoses more likely to 
develop in modified conduits or alternate or spliced vein 
conduits, or were patient risk factors such as smoking, 
hyperlipidemia, or diabetes ignificant? 
Dr. Curtis A. Erickson. We do conduct a detailed 
intraoperative assessment of our grafts using velocity 
spectral analysis and, more recently, duplex scanning. We 
use angioscopy selectively to define any graft pathologic 
condition. We believe these modalities identify most 
technical defects that lead to early lesions and thereby 
eliminate the need to revise these grafts. 
There is no absolute threshold criteria for peak systolic 
velocity that provides our indication for intervention or 
angiography. In this review, velocities labeled abnormal will 
likely prompt closer intervals of surveillance. Velocities in 
excess of 300 cm/sec or velocity ratios greater than 3.5 
represent a serious flow disturbance. We use a multifacto- 
rial approach to determine which patients will undergo 
angiography and intervention. 
For immediate flow disturbance, we have observed a
spectrum of changes during follow-up but have been 
unable to define a consistent pattern regarding the fate of 
late versus early abnormalities. 
We agree with your observation that in late follow-up 
many abnormalities are diagnosed by low flow velocities 
and reduced limb pressures. Complete duplex examinations 
need not be performed for every late follow-up study. 
Selective flow velocities of representative s gments of the 
graft will be adequate to identify most abnormalities. 
In this series, risk factors such as smoking, hyperten- 
sion, or diabetes had no specific effect on the occurrence of 
abnormalities or secondary patency. In a report by Ber- 
gamini our group identified that modified conduits were 
more likely to require subsequent revision. 
Dr. Sergio SaUes-Cunha (Toledo, Ohio). Bandyk 
stated that when the graft velocity decreased from 70 
cm/sec to 40 cm/sec, the risk of failure increased. So I 
wonder how many of the defects in this series were detected 
by a drop in velocity versus a low velocity? Do you really 
need to operate on any stenosis that does not show a 
decrease in velocity or blood flow rate? 
Dr. Erickson. In the series low flow abnormalities 
included grafts where the flow velocity decreased or was 
below 45 cm/sec. It's basically a summary quantity for 
those particular values. 
Dr. Dennis F. Bandyk (Tampa, Fla.). My comments 
involve clarification of the long-term durability of the in 
situ saphenous vein bypass. The value of this study was its 
evaluation of the late failure modes of this conduit. In prior 
reports, the Milwaukee group described the natural history 
of the in situ bypass during the first 5 years after operation. 
We found that approximately one half of the arterialized 
veins were completely normal by duplex scanning after 5 
years. 11 Since that report, the number of grafts that had 
been monitored beyond 5 years has doubled. What was the 
incidence of a graft with a normal duplex scan result at 5 
years developing a subsequent problem that required 
revision? Did any of these grafts fail? 
My second question concerns the use of the termgraft 
surveillance in this study. As I reviewed the data in the 
manuscript, late problems were not due to defects in the 
venous conduit, but progression of atherosclerosis led to 
most of the secondary procedures performed. Was this the 
authors' conclusion as well? Thus graft surveillance meth- 
ods must evaluate not only the graft but also the inflow and 
outflow arteries. 
My last question relates to the diagnostic accuracy of 
the vascular laboratory. How many of the late lesions that 
were repaired were symptomatic? Or did these patients 
have symptoms and did noninvasive testing confirm the 
presence of a "failing graft" rather than uncover an 
asymptomatic "graft-threatening" lesion? 
Dr. Erickson. If a graft was hemodynamically normal 
at 5 years, the chance of development ofany abnormalities 
of the type that we have called significant was still approxi- 
mately 30%. With surveillance of older grafts, the percent- 
age of inflow and outflow abnormalities increased signifi- 
cantly compared with abnormalities that developed in the 
conduit of the graft. In this series we do not have a marker 
for the occurrence of symptoms, and therefore we cannot 
identify which patients had development ofsymptoms and 
subsequently had a graft abnormality documented. This 
would be an interesting question to investigate. 
